These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 24141009)

  • 41. A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma.
    Corso A; Arcaini L; Caberlon S; Zappasodi P; Mangiacavalli S; Lorenzi A; Rusconi C; Troletti D; Maiocchi MA; Pascutto C; Morra E; Lazzarino M
    Haematologica; 2002 Oct; 87(10):1041-5. PubMed ID: 12368158
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma.
    Zimmerman TM; Michelson GC; Mick R; Grinblatt DL; Williams SF
    J Clin Apher; 1999; 14(1):31-4. PubMed ID: 10355661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma.
    Annunziata M; Celentano M; Pocali B; D'Amico MR; Palmieri S; Viola A; Copia C; Falco C; Del Vecchio L; Ferrara F
    Ann Hematol; 2006 Jun; 85(6):394-9. PubMed ID: 16538502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
    Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
    Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients.
    Nowrousian MR; Waschke S; Bojko P; Welt A; Schuett P; Ebeling P; Flasshove M; Moritz T; Schuette J; Seeber S
    Ann Oncol; 2003; 14 Suppl 1():i29-36. PubMed ID: 12736228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
    Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
    Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
    Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients.
    Watts MJ; Ings SJ; Leverett D; MacMillan A; Devereux S; Goldstone AH; Linch DC
    Br J Cancer; 2000 Jan; 82(2):278-82. PubMed ID: 10646877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
    Vogel W; Kunert C; Blumenstengel K; Fricke HJ; Kath R; Sayer HG; Höffken K
    J Cancer Res Clin Oncol; 1998; 124(6):341-5. PubMed ID: 9692843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.
    Mahindra A; Bolwell BJ; Rybicki L; Elder P; Kalaycio M; Dean R; Avalos B; Sobecks R; Tench S; Andresen S; Pohlman B; Sweetenham J; Devine S; Copelan E
    Bone Marrow Transplant; 2012 Feb; 47(2):231-5. PubMed ID: 21460870
    [TBL] [Abstract][Full Text] [Related]  

  • 54. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment.
    Milone G; Leotta S; Indelicato F; Mercurio S; Moschetti G; Di Raimondo F; Tornello A; Consoli U; Guido G; Giustolisi R
    Bone Marrow Transplant; 2003 May; 31(9):747-54. PubMed ID: 12732880
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide.
    McQuaker IG; Haynes AP; Stainer C; Anderson S; Russell NH
    Br J Haematol; 1997 Jul; 98(1):228-33. PubMed ID: 9233591
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study Group.
    Itoh K; Ohtsu T; Sasaki Y; Ogura M; Morishima Y; Kasai M; Chou T; Yoshida K; Ohno T; Mizorogi F; Uike N; Sai T; Taniwaki M; Ikeda S; Tobinai K
    Leuk Lymphoma; 2000 Aug; 38(5-6):521-32. PubMed ID: 10953973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders.
    Altés A; López R; Martino R; Martinez C; Cabezudo E; Muñoz L; Santamaría A; Perea G; Briones J; Salar A; Sureda A; Brunet S; Madoz P; Sierra J
    Bone Marrow Transplant; 2000 Jul; 26(2):127-32. PubMed ID: 10918421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [DA-EPOCH Chemotherapy Combined with G-CSF Effectively Mobilizes Autologous PBHSC in NHL Patients].
    Liao LS; Wei TN; Zheng ZH; Qu S; Xie Y; Wang ZH; Chen BY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1670-1674. PubMed ID: 29262895
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
    Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
    J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.